

Date: 11.08.2018

To,
The Secretary,
The B.S.E Limited
Floor 25, P.J. Towers,
Dalal Street,
Mumbai - 400 001

Sub: Submission of Un-Audited Standalone Financials Results of the Company and Limited Review Report as per Provisions of Regulation 30, 33 of SEBI (LODR) Regulations, 2015.

Please find enclosed here with the following Documents in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015:

1. Financial Results: Un-Audited Standalone Financial Results of the company for the First Quarter Ended 30th June, 2018.
2. Limited Review Report: A Certified Copy of the Limited Review Report on Standalone Financials for the First Quarter Ended 30th June, 2018 by the Auditors.
3. Appointment of Internal Auditor: A Certified Copy of the Outcome/Board Resolution for Appointment of Internal Auditor.

This is for your Information and Necessary Records.

Thanking you
For TRIMURTHI LIMITED



Arun Kumar Bhangadia
Managing Director
DIN: 00021024

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S, INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

Date: 11.08.2018

To,
The Secretary,
The B.S.E Limited
Floor 25, P.J. Towers,
Dalal Street,
Mumbai- 400 001

Sub: Outcome of the Board Meeting held on 11/08/2018 as per Regulation 30, 33 of
SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

The Board of Directors of the Company at its meeting held today, Saturday, the 11th day of August, 2018 at Registered Office, have approved and taken on record the following:

1. The Board has considered and approved the minutes of the previous board meeting.
2. The Board has considered and approved the Unaudited Standalone Financial Results for the First Quarter ended 30th June, 2018 along with Limited Review Report issued by the Statutory Auditors of the Company in compliance with Indian Accounting Standards (Ind-AS), SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013.
3. Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 read with Para A of Part A of Schedule III to said Regulation and also read with SEBI Circular no CIR/CFD/CMD/4/2015 dated September 9, 2015, this is to inform you that M/s P C N & Associates, Chartered Accountants has been appointed as Internal Auditors of the Company for the Financial Year 2018.

Date of Appointment: 11/08/2018

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

Details of Internal Auditors:

Name : P C N & Associates., Chartered Accountants
(Formerly known as Chandra Babu Naidu & Co.,)

FRN : 016016S


Address : P C N & Associates,
CHARTERED ACCOUNTANTS
Plot No: 12, "N Heights"
Ground Floor, Software Layout Unit,
Cyberabad, Hyderabad-500081
Tel: (91-40) 23119499
Email: pcnassociates@yahoo.com

There being no other matter meeting of the Board of Directors concluded with the vote of thanks.

The Meeting of the Board of Directors of the company commenced at 03.30 P.M. and Concluded at 05:00 PM

Request you to take same on records.

Thanking you
for TRIMURTHI LIMITED



Arun Kumar Bhangadia
Managing Director
DIN: 00021024

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

TRIMURTHI LIMITED
 (Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)

4-4-231/L/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095.

**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS
 FOR THE QUARTER ENDED 30TH JUNE 2018**

Rs. in Lakhs

PARTICULARS	QUARTER ENDED 30.06.2018 (UNAUDITED)	QUARTER ENDED 31.03.2018 (AUDITED)	QUARTER ENDED 30.06.2017 (UNAUDITED)	YEAR ENDED 31.03.2018 (AUDITED)
1. INCOME				
INCOME FROM OPERATIONS	104.44	128.50	30.36	311.16
OTHER INCOME	0.86	(0.91)	22.64	1.31
TOTAL INCOME	105.30	127.59	59.00	312.47
2. EXPENSES				
PURCHASES	75.64	84.97	0.29	199.22
COST OF MATERIALS CONSUMED	-	-	-	-
MANUFACTURING EXPENSES	-	-	-	0
WORK IN PROGRESS AND STOCK IN TRADE	7.16	19.59	21.92	11.62
RENT	0.65	0.75	0.75	3.00
EMPLOYEE BENEFITS EXPENSE	6.22	9.55	5.81	28.35
FINANCE COSTS	-	-	-	-
DEPRECIATION AND AMORTISATION EXPENSES	3.82	3.43	3.69	15.39
OTHER EXPENSES	11.74	14.08	5.36	25.59
TOTAL EXPENSES	104.44	136.37	37.82	283.17
3. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE EXCEPTIONAL ITEMS (1-2)	0.87	(4.78)	15.18	29.30
4. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS				
5. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (3-4)	0.87	(5.92)	15.18	28.16
6. TAX EXPENSES				
-CURRENT TAX	0.29	(1.83)	4.66	8.31
-TAX ADJUSTMENTS RELATING TO EARLIER YEARS	-	-	-	-
-DEFERRED TAX (NET)	(2.79)	3.39	(0.29)	1.74
7. NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (5-6)	3.37	(7.48)	10.81	18.11
8. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS				
9. IAA EXPENSES FOR DISCONTINUED OPERATIONS	-	-	-	-
10. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (8-9)	-	-	-	-
11. PROFIT/(LOSS) FOR THE PERIOD (7+10)	3.37	(7.48)	10.81	18.11
12. OTHER COMPREHENSIVE INCOME				
A. (i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS				
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS				
B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS	(0.57)	4.96	-	4.96
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL BE RECLASSIFIED TO				
13. TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12) (COMPRISING PROFIT (LOSS) AND OTHER COMPREHENSIVE INCOME)	(1.20)	(2.52)	10.81	23.07
14. EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATION):				
(i) BASIC	0.04	(0.09)	0.13	0.22
(ii) DILUTED	0.04	(0.09)	0.13	0.22
15. EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATION):				
(i) BASIC	-	-	-	-
(ii) DILUTED	-	-	-	-
16. EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATION):				
(i) BASIC	0.04	(0.09)	0.13	0.22
(ii) DILUTED	0.04	(0.09)	0.13	0.22



TRIMURTHI LIMITED
 (Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)

SCHEDULE III OF THE COMPANIES ACT 2013

PART-II

	PARTICULARS	QUARTER ENDED 30/06/2018 (UNAUDITED)	QUARTER ENDED 31/03/2018 (AUDITED)	QUARTER ENDED 30/06/2017 (UNAUDITED)	YEAR ENDED 31/03/2018 (AUDITED)
A. PARTICULARS OF SHARE HOLDING					
1.	Public Share Holding				
	- Number of Shares	2900600	2900600	2900600	2900600
	- Percentage of shareholding	35.81%	35.81%	35.18%	35.18%
2.	Promoters and promoter group shareholding				
a.	Pledged / encumbered				
	- No of Equity Shares	-NIL-	-NIL-	-NIL-	-NIL-
	- Percentage of Shares (of the shareholding of promoter and promoter group)	-NIL-	-NIL-	-NIL-	-NIL-
	- Percentage of Shares (of the total share capital of the company)	-NIL-	-NIL-	-NIL-	-NIL-
b.	Non encumbered				
	- No of Equity Shares	5199400	5199400	5199400	5199400
	- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
	- Percentage of Shares (of the total share capital of the company)	64.19%	64.19%	64.19%	64.19%

Particulars	3 Months Ended (30/06/2018)
B. Investor Complaints	
Pending at the beginning of the quarter	-NIL-
Received during the quarter	-NIL-
Disposed during the quarter	-NIL-
Remaining unresolved during the quarter	-NIL-



TRIMURTHI LIMITED
 (Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)
 4-4-231/I/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095.
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS
FOR THE QUARTER ENDED 30TH JUNE 2018

Segment Reporting

	PARTICULARS	QUARTER ENDED 30.06.2018 (UNAUDITED)	QUARTER ENDED 31.03.2018 (AUDITED)	QUARTER ENDED 30.06.2017 (UNAUDITED)	YEAR ENDED 31.03.2018 (AUDITED)
1.	Segment Revenue				
a.	Pharma Business	0.00	0.00	0.00	0.00
b.	Financial Services	16.98	13.90	20.66	76.96
c.	Investments	0	0.00	0.00	0.00
d.	Trading in Shares	11.27	67.80	32.34	189.63
e.	Foods	77.05	45.88	0.00	45.88
Total		105.30	127.58	53.00	312.47
Less:	Inter Segment Revenue	-Nil-	-Nil-	-Nil-	-Nil-
	Net Sales/ Income From Operations		105.30	127.58	53.00
2.	Segment Profits (Before tax & Interest From Each Segment)				
a.	Pharma Business	0	0.00	0.00	0.00
b.	Financial Services	13.64	10.92	15.63	55.32
c.	Investments	0	0.00	0.00	0.00
d.	Trading in Shares	1.78	1.73	(0.45)	(8.58)
e.	Foods	(14.55)	(18.58)	0.00	(18.58)
Total		0.87	(5.93)	15.18	28.16
Less:					
i.	Interest	-Nil-	-Nil-	-Nil-	-Nil-
ii.	Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-
iii.	Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-
	Total Profit Before Tax	0.87	(5.93)	15.18	28.16
3.	Capital Employed				
a.	Pharma Business	0	0.00	0.00	0.00
b.	Financial Services	531.84	521.58	678.97	521.58
c.	Investments	312.82	292.00	184.34	292.00
d.	Trading in Shares	315.54	356.89	305.74	356.89
e.	Foods	19.78	11.78	0.00	11.78
	Total	1179.38	1382.24	1169.05	1382.24



TRIMURTHI LIMITED
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)
44-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095.
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS
FOR THE QUARTER ENDED 30TH JUNE 2018

Notes:

- 1 The format for the Unaudited quarterly results as prescribed in SEBI Circular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI Circular CRI/CFD/FAC/62/2016 dated July 5, 2016.
- 2 There is a possibility that these quarterly financial results may require adjustment before compiling the final Ind AS financial statements as of and for the year ending March 31, 2018 due to changes in financial reporting requirements arising from new or revised standards or interpretations issued by MCA or changes in the use of one or more optional exemptions from retrospective application of certain Ind AS as permitted under Ind AS 101.
- 3 Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- 4 The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 11th August 2018. The limited review of the financial results for the Quarter ended 30th June 2018 has been carried out by the statutory auditors of the Company.
- 5 The above standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34- Interim Financial Reporting prescribed under Section 133 of the Companies Act,2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.

Place : Hyderabad
Date : 11th August,2018.





P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

Limited Review Report- Standalone Financial Results

To

The Board of Directors,
Trimurthi Limited (Formerly known as Trimurthi Drugs & Pharmaceuticals Limited),
Hyderabad,
India.

Limited Review Report for the quarter ended 30th June 2018.

1. We have reviewed the accompanying statement of unaudited standalone financial results of Trimurthi Limited (the 'Company') for the quarter ended June 30th, 2018 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/ 62/2016 dated July 5, 2016.
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015, read with SEBI Circular No. CIR/CFD/ FAC/62/ 2016 dated July 5, 2016 is the responsibility of the Company's management and has been approved by the Board of Directors of the Company in their meeting held on 11th August, 2018. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.





P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/ 62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.
Chartered Accountants
FRN: 007257S

A. Krishna Rao
Partner
M.No. 020085



Place: Hyderabad
Date: 11.08.2018